TOI vs ONCO

For growth investors, The Oncology Institute, Inc.

(TOI) is the stronger pick with 27. 8% revenue growth year-over-year, versus -67. 7% for Onconetix, Inc. (ONCO). Analysts rate The Oncology Institute, Inc. (TOI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, The Oncology Institute, Inc.

(TOI) delivered a total return of -47. 4%, compared to -100. 0% for Onconetix, Inc. (ONCO). Over 10 years, the gap is even starker: TOI returned -45. 3% versus ONCO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Onconetix, Inc.

(ONCO) is the lower-risk stock at 1. 33β versus The Oncology Institute, Inc. 's 1. 95β — meaning TOI is approximately 47% more volatile than ONCO relative to the S&P 500.

By revenue growth (latest reported year), The Oncology Institute, Inc.

(TOI) is pulling ahead at 27. 8% versus -67. 7% for Onconetix, Inc. (ONCO). On earnings-per-share growth, the picture is similar: Onconetix, Inc. grew EPS 99. 1% year-over-year, compared to 23. 9% for The Oncology Institute, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Oncology Institute, Inc.

(TOI) is the more profitable company, earning -12. 1% net margin versus -1721. 0% for Onconetix, Inc. — meaning it keeps -12. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TOI leads at -7. 2% versus -778. 2% for ONCO. At the gross margin level — before operating expenses — ONCO leads at 77. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Onconetix, Inc.

(ONCO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. The Oncology Institute, Inc. (TOI) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ONCO: -100. 0%, TOI: -45. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TOI is a small-cap high-growth stock; ONCO is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.